With the largest installed base of over 10,000 BenchMark IHC/ISH staining platforms worldwide, and a powerful affiliate network in 100+ countries, our partners have the broadest access to patients.
With the largest installed base of over 10,000 BenchMark IHC/ISH staining platforms worldwide, and a powerful affiliate network in 100+ countries, our partners have the broadest access to patients.
By activating early adopters, we gather early real-world performance data to generate evidence that drives awareness and supports uptake. We also engage with payers and facilitate medical and sales training for our affiliates.
We bridge the gap to ensure there is no delay in patient access to your therapy. We engage earlier with KOLs and centers of excellence, prepare labs and deliver pathologist education to establish testing readiness.
Marketing and market access teams coordinate launches globally and locally, ensuring all critical tools for planning and execution of global launch strategy are available across Roche and pharma affiliates, worldwide.
CASE STUDY
Find out how we enabled significant access to personalized therapy for cancer patients.
Our traditional and accelerated commercialization models build awareness and drive adoption through a broad range of activities from pre-launch readiness to post-launch marketing.